Printer Friendly

Research Report on Pricing and Reimbursement Issues in Psychiatry Available Now.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47926) has announced the addition of Pricing and Reimbursement Issues in Psychiatry to their offering.

Compared with many other disease areas (e.g., cancer, immune diseases), the costs of drug therapy for psychiatric disorders are relatively modest. However, the World Health Organization forecasts that by 2020, depression -- just one of a spectrum of psychiatric disorders--will be the second most frequent cause of death and disability in the world and the leading cause in industrialized nations. In anticipation of this surge, payers in the major pharmaceutical markets would like to exercise greater control over the use of psychiatric drugs.

Get the Answers You Need to Shape Your Strategy

In just the major pharmaceutical markets, the number of people afflicted with common psychiatric disorders will increase, and spending on drug therapies will grow steadily. How will payers try to curb spending on psychiatric drugs? The prices of generic antidepressants are much higher in Europe than in the United States. What factors are behind this differential? Pharmacy benefits offered by U.S. private insurers tend to be considerably more generous

than the coverage provided by Medicare and Medicaid, but cost-containment measures are proliferating. What steps are private insurers taking to control drug expenditures? Medicare Part D offers outpatient drug coverage to all Medicare beneficiaries who choose to enroll. What will be the standard benefit design of Part D in 2007?

The U.S. Medicaid program is a major source of funding for psychiatric drugs--especially atypical antipsychotics. What cost-cutting measures are state Medicaid programs instituting to control drug expenditures?

France has the lowest average prices of any of the major pharmaceutical markets for branded antidepressants. Nevertheless, the government would like to reduce spending on this drug class. What steps has the Caisse Nationale de l'Assurance Maladie taken to stimulate France's relatively immature generics market? How successful have these measures been so far?

Scope

Drug classes covered: antidepressants, antipsychotics, psychostimulants, hypnotics, sedatives, and anxiolytics.

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Price comparisons: comparisons of international pricing of the psychiatric drug classes in this report.

Reimbursement: overview of the general environment in each market and analysis of factors specific to individual psychiatric drug classes.

Market outlook: pricing and reimbursement implications for the manufacturers of psychiatric drugs.

Contents

Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

International Price Comparisons of Psychiatric Drugs

Overview

Antidepressants

Antipsychotics

Psychostimulants

Hypnotics, Sedatives, and Anxiolytics

Reimbursement Environment

United States

General Environment

Private Insurance

Medicare

Sidebar: Patient Assistance Programs--An Important Source of Drug Funding

Medicaid

Antidepressants

Antipsychotics

Psychostimulants

Hypnotics, Sedatives, and Anxiolytics

France

General Environment

Antidepressants

Antipsychotics

Psychostimulants

Hypnotics, Sedatives, and Anxiolytics

Germany

General Environment

Antidepressants

Antipsychotics

Psychostimulants

Hypnotics, Sedatives, and Anxiolytics

Italy

General Environment

Antidepressants

Antipsychotics

Psychostimulants

Hypnotics, Sedatives, and Anxiolytics

Spain

General Environment

Antidepressants

Antipsychotics

Psychostimulants

Hypnotics, Sedatives, and Anxiolytics

United Kingdom

General Environment

Antidepressants

Antipsychotics

Psychostimulants

Hypnotics, Sedatives, and Anxiolytics

For more information visit http://www.researchandmarkets.com/reports/c47926

Source: Decision Resources
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 5, 2007
Words:498
Previous Article:EHNAC Approves Candidacy Status for Post-N-Track Corporation.
Next Article:Strong Growth Potential in European Pay Later Card IT Market.
Topics:


Related Articles
Mental cases.
Under treatment: as oncologists struggle with the traditional process of charging patients for chemotherapy medication, insurers are offering their...
Integrated health care: improving client care while providing opportunities for mental health counselors.
UO expert calls for honest fight against child sex abuse.
W.W. Norton & Company.
Financial implications of contracting for acquisition programs.
Psychology In The Genome And Neuroscience Era.
Mixed expense reimbursements and unreturned overpayments disqualified entire accountable plan.
Research Administration and Management.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters